Browse News
Filter News
Found 84 articles
-
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer
3/14/2024
Endeavor BioMedicines today announced the appointment of Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer (CFO).
-
Synthetic biology company Pearl Bio announced Tuesday it has entered into a license and collaboration agreement with Merck to discover biologic therapies comprising non-standard amino acids.
-
Capstan Therapeutics Appoints Ramin Farzaneh-Far, M.D., as Chief Medical Officer and Announces Key Business Leadership Promotion
1/8/2024
Capstan Therapeutics, Inc. announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to Senior Vice President, Corporate Development.
-
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors
12/19/2023
Endeavor BioMedicines announced that the company has appointed Enoch Kariuki, Pharm.D. to the Endeavor BioMedicines Board of Directors.
-
The French pharma drops another BTK inhibitor program from Principia and an anti-TNFa from Ablynx.
-
Capstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel
3/22/2023
Capstan Therapeutics, Inc. today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.
-
Covalent biologic company Enlaza launches with $61M in seed financing.
-
Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for their SHP2 inhibitor drug candidate,
-
Sanofi will drop its IL-2 candidate, citing a lack of efficacy in the early stages of data collection, the company announced in its Q3 report Friday.
-
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
10/3/2022
Incyte announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo.
-
Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering
9/14/2022
Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering.
-
Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development
7/19/2022
Medikine, Inc., a biopharmaceutical company developing transformative therapeutics for cancer, autoimmune disorders, and infectious diseases using its novel PEPTIKINE™ technology, today announced it has initiated dosing of MDK-703, an extended half-life IL-7 mimetic.
-
ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development
6/2/2022
ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that Jill M. Mooney, Ph.D., has joined as Senior Vice President of Research and Development (R&D).
-
Gennao Bio Strengthens Board of Directors with Appointments of Peter Thompson, M.D., and Bradley Campbell
3/17/2022
Gennao Bio today announced the appointments of Peter Thompson, M.D., and Bradley Campbell to its Board of Directors.
-
BioSpace Movers & Shakers, Oct. 29
10/29/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Onchilles Pharma Appoints Christopher Twitty, Ph.D., Chief Scientific Officer
10/26/2021
Onchilles Pharma announced today the expansion of the company’s scientific team with key leadership appointments.
-
Tentarix Biotherapeutics Emerges with $50 Million Series A
10/14/2021
Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.
-
Asher Bio began two years ago and raised $55 million in a Series A financing round this March to take forward a series of engineered cytokines that aim to eliminate both the toxicities and the loss of efficacy in immunotherapy.
-
BioSpace Movers & Shakers, Aug. 27
8/27/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Lengo Therapeutics Appoints Enoch K. Kariuki as Chief Executive Officer
6/28/2021
Lengo Therapeutics today announced the appointment of Enoch K. Kariuki, Pharm.D., as Chief Executive Officer.